Details

Autor(en) / Beteiligte

• Somaiah, Neeta
• Tap, William

Titel

MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action

Ist Teil von

• Cancer treatment reviews, 2024-01, Vol.122, p.102668-102668, Article 102668

Ort / Verlag

Netherlands

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Well-differentiated and dedifferentiated liposarcomas (WDLPS and DDLPS) are rare tumors that arise from lipocytes in soft tissue. There is a high unmet need in patients with these liposarcomas given poor outcomes, particularly for DDLPS. WDLPS and DDLPS share important genetic and histological characteristics - most notably, the amplification of the 2 genes MDM2 and CDK4. Both genes are considered oncogenes because of their ability to shut down tumor suppressor pathways. There are multiple therapeutic approaches that aim to target MDM2 and CDK4 activity for the purpose of restoring intrinsic tumor suppressor cellular response and terminating oncogenesis. However, current understanding of the molecular mechanisms involved in WDLPS and DDLPS pathology is limited. In recent years, significant efforts have been made to refine and implement targeted therapy for this patient population. The use of patient-derived cell and tumor xenograft models has been an important tool for recapitulating WDLPS and DDLPS biology. These models also offer valuable insights for drug development and drug combination studies. Here we offer a review of the current understanding of WDLPS and DDLPS biology and its therapeutic implications.